Doximity (DOCS) is likely bracing for a wider range of outcomes in 2025 amid strong near-term conditions, Morgan Stanley said in a Thursday note.
"Near term conditions are robust and should be supportive to guiding in line with the Street estimate," the report said.
Still, macro risks have intensified, with pharma companies contending with uncertainty around tariffs and disruptions at the US Food and Drug Administration, the note added.
"As such, line of sight into the back half of the year is clouded," the report said.
Morgan Stanley cut its price target to $60 from $71 while keeping its equalweight rating to reflect multiple contraction.
Price: 55.07, Change: +0.85, Percent Change: +1.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.